Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 20, 2011 - Issue 10
Submit an article Journal homepage
870
Views
87
CrossRef citations to date
0
Altmetric
Drug Evaluations

Entinostat for treatment of solid tumors and hematologic malignancies

Jeffrey Knipstein The University of Colorado School of Medicine, Department of Pediatrics and Children's Hospital Colorado, Center for Cancer and Blood Disorders, Box B115 TCH, 13123 East 16th Avenue, Aurora, CO 80045, USA
, MD &
Lia Gore The University of Colorado School of Medicine, Departments of Pediatrics and Medical Oncology, Director Early Phase Hematological Malignancies Program University of Colorado Cancer Center; and Director of Experimental Therapeutics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Box B115, 13123 East 16th Avenue, Aurora, CO 80045, USA+1 720 777 6772; +1 720 777 7289; [email protected]
, MD
Pages 1455-1467 | Published online: 02 Sep 2011

Citations (87)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Ma Su, Xingyu Gong & Feng Liu. (2021) An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. Expert Opinion on Drug Discovery 16:7, pages 745-761.
Read now
Kristin C. Hicks, Massimo Fantini, Renee N. Donahue, Angie Schwab, Karin M. Knudson, Sarah R. Tritsch, Caroline Jochems, Paul E. Clavijo, Clint T. Allen, James W. Hodge, Kwong Y. Tsang, Jeffrey Schlom & Sofia R. Gameiro. (2018) Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. OncoImmunology 7:11.
Read now
Hai-Tao Qin, Huan-Qiu Li & Feng Liu. (2017) Selective histone deacetylase small molecule inhibitors: recent progress and perspectives. Expert Opinion on Therapeutic Patents 27:5, pages 621-636.
Read now
Rossana Ruiz, Luis E Raez & Christian Rolfo. (2015) Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs 24:8, pages 1101-1109.
Read now
Geneviève P Delcuve, Dilshad H Khan & James R Davie. (2013) Targeting class I histone deacetylases in cancer therapy. Expert Opinion on Therapeutic Targets 17:1, pages 29-41.
Read now

Articles from other publishers (82)

Miao Yan, Heng Cao, Kangjia Tao, Bing Xiao, Yifan Chu, Ding Ma, Xiaoyuan Huang, Yingyan Han & Teng Ji. (2023) HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers. Gene 885, pages 147704.
Crossref
Léa Madegard, Melissa Girard, Benjamin Riss Yaw, Karine Porte, Davide Audisio, Sébastien Papot & Frédéric Taran. (2023) Bioorthogonal Drug Release from Nanometric Micelles in Living Cells. Chemistry – A European Journal 29:43.
Crossref
Edoardo D'Angelo, Chiara Pastrello, Andrea Biccari, Asia Marangio, Francesca Sensi, Sara Crotti, Matteo Fassan, Igor Jurisica, Salvatore Pucciarelli & Marco Agostini. (2023) An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5‐fluorouracil . International Journal of Cancer 153:2, pages 437-449.
Crossref
Rourou Li, Yujia Tian, Zhenwu Yang, Yueshan Ji, Jiaqi Ding & Aixia Yan. (2022) Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods. Molecular Diversity 27:3, pages 1037-1051.
Crossref
Vinit Singh Baghel, Sapnita Shinde, Vibha Sinha, Vineeta Dixit, Atul Kumar Tiwari, Saurabh Saxena, Naveen Kumar Vishvakarma, Dhananjay Shukla & Prashant Bhatt. 2023. Transcription and Translation in Health and Disease. Transcription and Translation in Health and Disease 287 324 .
Asad Mohammad & Sudhakar Jha. (2022) Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment. Cancers 15:1, pages 215.
Crossref
Jasmine M. Cross, Megan E. Coulson, Joshua P. Smalley, Wiktoria A. Pytel, Ozair Ismail, Justin S. Trory, Shaun M. Cowley & James T. Hodgkinson. (2022) A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. RSC Medicinal Chemistry 13:12, pages 1634-1639.
Crossref
Jingru Yang, Cong Song & Xianquan Zhan. (2022) The role of protein acetylation in carcinogenesis and targeted drug discovery. Frontiers in Endocrinology 13.
Crossref
Jiayu Wang, Jiaxing Li, Xin Zhang, Min Zhang, Xiaopeng Hu & Hang Yin. (2022) Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression. Frontiers in Molecular Biosciences 9.
Crossref
Siddhartha Das Pramanik, Amit Kumar Halder, Ushmita Mukherjee, Dharmendra Kumar, Yadu Nandan Dey & Mogana R. (2022) Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Frontiers in Chemistry 10.
Crossref
Xiu Gu, Xin-Yan Peng, Hao Zhang, Bo Han, Min-Ru Jiao, Qiu-Shi Chen & Qing-Wei Zhang. (2022) Discovery of Indole-Containing Benzamide Derivatives as HDAC1 Inhibitors with In Vitro and In Vivo Antitumor Activities. Pharmaceutical Fronts 04:02, pages e61-e70.
Crossref
Liyi Zhang. (2022) E2112 —Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell? . Thoracic Cancer 13:9, pages 1237-1239.
Crossref
Simona Dedoni, Alessandra Olianas, Barbara Manconi, Maria Collu, Barbara Tuveri, Maria Elena Vincis, Maria C. Olianas & Pierluigi Onali. (2022) Upregulation of p75NTR by Histone Deacetylase Inhibitors Sensitizes Human Neuroblastoma Cells to Targeted Immunotoxin-Induced Apoptosis. International Journal of Molecular Sciences 23:7, pages 3849.
Crossref
Vivek BoraDhwani PatelKaid JoharRamesh K. GoyalBhoomika M. Patel. (2022) Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia. Canadian Journal of Physiology and Pharmacology 100:3, pages 240-251.
Crossref
Shengrui Feng & Daniel D. De Carvalho. (2021) Clinical advances in targeting epigenetics for cancer therapy. The FEBS Journal 289:5, pages 1214-1239.
Crossref
Ping-Ting Mao, Wei-Bao He, Xi Mai, Li-Hua Feng, Na Li, Yi-Jing Liao, Cai-Sheng Zhu, Jian Li, Ting Chen, Shu-Hao Liu, Qi-Ming Zhang & Ling He. (2022) Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic & Medicinal Chemistry 56, pages 116599.
Crossref
Iwona T. Myszor, Snaevar Sigurdsson, Alexia Ros Viktorsdottir, Birgitta Agerberth, Eeva-Liisa Eskelinen, Margret Helga Ogmundsdottir & Gudmundur H. Gudmundsson. (2022) The Novel Inducer of Innate Immunity HO53 Stimulates Autophagy in Human Airway Epithelial Cells. Journal of Innate Immunity 14:5, pages 477-492.
Crossref
Yiyue Feng, Yingmei Lu, Junfang Li, Honghua Zhang, Zhao Li, Hanzhong Feng, Xuemei Deng, Dan Liu, Tao Shi, Weifan Jiang, Yongxing He, Jian Zhang & Zhen Wang. (2022) Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo. European Journal of Medicinal Chemistry 227, pages 113888.
Crossref
Ganesh Routholla, Sravani Pulya, Tarun Patel, Nilanjan Adhikari, Sk. Abdul Amin, Milan Paul, Srividya Bhagavatula, Swati Biswas, Tarun Jha & Balaram Ghosh. (2021) Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model. Bioorganic Chemistry 117, pages 105446.
Crossref
Zixue Zhang, Qingwei Zhang, Hao Zhang, Minru Jiao, Zheng Guo, Xinyan Peng, Lei Fu & Jianqi Li. (2021) Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities. Bioorganic Chemistry 117, pages 105407.
Crossref
Oxana Schmidt, Nadja Nehls, Carolin Prexler, Kristina von Heyking, Tanja Groll, Katharina Pardon, Heathcliff D. Garcia, Tim Hensel, Dennis Gürgen, Anton G. Henssen, Angelika Eggert, Katja Steiger, Stefan Burdach & Günther H. S. Richter. (2021) Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard L. Piekarz, Karen L. Smith, Ursa A. Brown-Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, George T. Budd, Ellis G. Levine, Melanie E. Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff & Joseph A. Sparano. (2021) E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology 39:28, pages 3171-3181.
Crossref
Hajar Sirous, Giuseppe Campiani, Vincenzo Calderone & Simone Brogi. (2021) Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Computers in Biology and Medicine 137, pages 104808.
Crossref
Ganesh Routholla, Sravani Pulya, Tarun Patel, Sk. Abdul Amin, Nilanjan Adhikari, Swati Biswas, Tarun Jha & Balaram Ghosh. (2021) Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. Bioorganic Chemistry 114, pages 105050.
Crossref
Yang Xi, Dai Jingying, Li Chenglong, Zheng Hong, Zhang Rong, Wang Xiaodong, Wang Chunsen & Huang Xiaobing. (2021) Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients. Frontiers in Molecular Biosciences 7.
Crossref
Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni & Majid Safa. (2021) MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. Journal of Hematology & Oncology 14:1.
Crossref
Liyun Luo, Zhijie Zhang, Ni Qiu, Li Ling, Xiaoting Jia, Ying Song, Hongsheng Li, Jiansheng Li, Hui Lyu, Hao Liu, Zhimin He, Bolin Liu & Guopei Zheng. (2021) Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nature Communications 12:1.
Crossref
Mohammed Ghiboub, Ahmed M. I. Elfiky, Menno P. J. de Winther, Nicola R. Harker, David F. Tough & Wouter J. de Jonge. (2021) Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives. Journal of Personalized Medicine 11:5, pages 336.
Crossref
Kunal Nepali & Jing-Ping Liou. (2021) Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science 28:1.
Crossref
Mio Harachi, Kenta Masui, Webster K. Cavenee, Paul S. Mischel & Noriyuki Shibata. (2021) Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer. Metabolites 11:4, pages 216.
Crossref
Holly L. Pacenta, Wendy Allen-Rhoades, David Langenau, Peter J. Houghton, Charles Keller, Christine M. Heske, Michael D. Deel, Corinne M. Linardic, Jack F. Shern, Elizabeth Stewart, Brian Turpin, Douglas J. Harrison, Javed Khan, Leo Mascarenhas, Stephen X. Skapek, William H. Meyer, Douglas S. Hawkins, Eleanor Y. Chen, James F. Amatruda, Pooja Hingorani & Theodore W. Laetsch. (2021) Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Journal of Clinical Medicine 10:7, pages 1416.
Crossref
Arshdeep Singh, Ting-Yu Chang, Navdeep Kaur, Kai-Cheng Hsu, Yun Yen, Tony Eight Lin, Mei-Jung Lai, Sung-Bau Lee & Jing-Ping Liou. (2021) CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. European Journal of Medicinal Chemistry 215, pages 113169.
Crossref
Han Li, Xiaoqing Xu, Yudi Zhang, Xianying Tang & Wenhua Li. (2020) Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner. European Journal of Pharmacology 888, pages 173575.
Crossref
Xiaopeng Peng, Zhiqiang Sun, Peihua Kuang & Jianjun Chen. (2020) Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European Journal of Medicinal Chemistry 208, pages 112831.
Crossref
M. Michael Dcona, Koushambi Mitra & Matthew C. T. Hartman. (2020) Photocontrolled activation of small molecule cancer therapeutics. RSC Medicinal Chemistry 11:9, pages 982-1002.
Crossref
Anita Mazloom, Nima Ghalehsari, Victor Gazivoda, Neil Nimkar, Sonal Paul, Peter Gregos, Janice Rateshwar & Uqba Khan. (2020) Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Journal of Clinical Medicine 9:8, pages 2533.
Crossref
Kunal Nepali, Ting-Yu Chang, Mei-Jung Lai, Kai-Cheng Hsu, Yun Yen, Tony Eight Lin, Sung-Bau Lee & Jing-Ping Liou. (2020) Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. European Journal of Medicinal Chemistry 196, pages 112291.
Crossref
Ozge Gumusay, Pietro Paolo Vitiello, Chiara Wabl, Ryan B. Corcoran, Alberto Bardelli & Hope S. Rugo. (2020) Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book:40, pages e292-e308.
Crossref
Hajar Sirous, Giuseppe Campiani, Simone Brogi, Vincenzo Calderone & Giulia Chemi. (2020) Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. Molecules 25:8, pages 1952.
Crossref
Rajat Sarkar, Suvankar Banerjee, Sk Abdul Amin, Nilanjan Adhikari & Tarun Jha. (2020) Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review. European Journal of Medicinal Chemistry 192, pages 112171.
Crossref
Kelly A. Hyndman. (2020) Histone Deacetylases in Kidney Physiology and Acute Kidney Injury. Seminars in Nephrology 40:2, pages 138-147.
Crossref
Bin DengQing LuoAlexander HalimQiuping LiuBingyu ZhangGuanbin Song. (2020) The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair. DNA and Cell Biology 39:2, pages 167-176.
Crossref
Shanshan Ma, Tengfei Liu, Ling Xu, Yaping Wang, Jiankang Zhou, Tuanjie Huang, Peng Li, Hongtao Liu, Yanting Zhang, Xinkui Zhou, Yuanbo Cui, Xingxing Zang, Yuming Wang & Fangxia Guan. (2019) Histone deacetylases inhibitor MS‐275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. Journal of Cellular Physiology 234:12, pages 22400-22410.
Crossref
Marcelo L. Ribeiro, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano & Gaël Roué. (2019) Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Frontiers in Genetics 10.
Crossref
Raushan T. Kurmasheva, Abhik Bandyopadhyay, Edward Favours, Vanessa Del Pozo, Samson Ghilu, Doris A. Phelps, Stephen W. Erickson, Cody J. Peer, William D. Figg, Malcolm A. Smith & Peter J. Houghton. (2019) Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models. Pediatric Blood & Cancer 66:8.
Crossref
Yan Ma, Michael Baltezor, Lian Rajewski, Jennifer Crow, Glenson Samuel, Vincent S. Staggs, Katherine M. Chastain, Jeffrey A. Toretsky, Scott J. Weir & Andrew K. Godwin. (2019) Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Journal of Molecular Medicine 97:7, pages 957-972.
Crossref
Veronika A. Myasoedova, Vasily Sukhorukov, Andrey V. Grechko, Dongwei Zhang, Elena Romanenko, Vawain Orekhov & Alexander N. Orekhov. (2019) Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. Current Pharmaceutical Design 25:6, pages 635-641.
Crossref
Iwona T. Myszor, Zahida Parveen, Håkan Ottosson, Peter Bergman, Birgitta Agerberth, Roger Strömberg & Gudmundur H. Gudmundsson. (2019) Novel aroylated phenylenediamine compounds enhance antimicrobial defense and maintain airway epithelial barrier integrity. Scientific Reports 9:1.
Crossref
Aparna Maiti, Qianya Qi, Xuan Peng, Li Yan, Kazuaki Takabe & Nitai Hait. (2019) Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells. International Journal of Oncology.
Crossref
Andrew E. Shouksmith, Fenil Shah, Michelle L. Grimard, Justyna M. Gawel, Yasir S. Raouf, Mulu Geletu, Angelika Berger-Becvar, Elvin D. de Araujo, H. Artee Luchman, William L. Heaton, David Bakhshinyan, Ashley A. Adile, Chitra Venugopal, Thomas O’Hare, Michael W. Deininger, Sheila K. Singh, Stephen F. Konieczny, Samuel Weiss, Melissa L. Fishel & Patrick T. Gunning. (2019) Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry 62:5, pages 2651-2665.
Crossref
Helai P. Mohammad, Olena Barbash & Caretha L. Creasy. (2019) Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nature Medicine 25:3, pages 403-418.
Crossref
Meran Keshawa Ediriweera, Kamani Hemamala Tennekoon & Sameera Ranganath Samarakoon. (2019) Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. Drug Discovery Today 24:3, pages 685-702.
Crossref
Nilanjan Adhikari, Sk. Abdul Amin, Prakruti Trivedi, Tarun Jha & Balaram Ghosh. (2018) HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches. European Journal of Medicinal Chemistry 157, pages 1127-1142.
Crossref
Sri Lakshmi Hyndavi Yeruva, Fengmin Zhao, Kathy D. Miller, Amye J. Tevaarwerk, Lynne I. Wagner, Robert J. Gray, Joseph A. Sparano & Roisin M. Connolly. (2018) E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. npj Breast Cancer 4:1.
Crossref
Richard L. BennettJonathan D. Licht. (2018) Targeting Epigenetics in Cancer. Annual Review of Pharmacology and Toxicology 58:1, pages 187-207.
Crossref
Roisin M Connolly, Michelle A Rudek & Richard Piekarz. (2017) Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncology 13:13, pages 1137-1148.
Crossref
Zihao Liu, Andrew J. Sanders, Gehao Liang, Erwei Song, Wen G. Jiang & Chang Gong. (2017) Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment. Molecular Cancer Therapeutics 16:5, pages 775-786.
Crossref
M.D. Cantley, A.C.W. Zannettino, P.M. Bartold, D.P. Fairlie & D.R. Haynes. (2017) Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone 95, pages 162-174.
Crossref
Kylie A. McLaughlin, Zsuzsanna Nemeth, Conor A. Bradley, Luke Humphreys, Izabela Stasik, Catherine Fenning, Joanna Majkut, Catherine Higgins, Nyree Crawford, Caitriona Holohan, Patrick G. Johnston, Timothy Harrison, Gerard G. Hanna, Karl T. Butterworth, Kevin M. Prise & Daniel B. Longley. (2016) FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics 15:10, pages 2432-2441.
Crossref
Yixuan Li & Edward Seto. (2016) HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harbor Perspectives in Medicine 6:10, pages a026831.
Crossref
Erica Miraglia, Frank Nylén, Katarina Johansson, Elias Arnér, Marcus Cebula, Susan Farmand, Håkan Ottosson, Roger Strömberg, Gudmundur H. Gudmundsson, Birgitta Agerberth & Peter Bergman. (2016) Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors. Scientific Reports 6:1.
Crossref
Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan & Bolin Liu. (2016) MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget 7:25, pages 37693-37713.
Crossref
Thea van den Bosch, Niek G.J. Leus, Tirza Timmerman & Frank J. Dekker. 2016. Drug Discovery in Cancer Epigenetics. Drug Discovery in Cancer Epigenetics 191 208 .
Charles M. MarsonChristopher J. MatthewsStephen J. AtkinsonNermina LamademaN. Shaun B. Thomas. (2015) Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N -(2-Aminophenyl)-benzamide Binding Unit . Journal of Medicinal Chemistry 58:17, pages 6803-6818.
Crossref
Gemma Di Pompo, Manuela Salerno, Dante Rotili, Sergio Valente, Clemens Zwergel, Sofia Avnet, Giovanna Lattanzi, Nicola Baldini & Antonello Mai. (2015) Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells. Journal of Medicinal Chemistry 58:9, pages 4073-4079.
Crossref
Jie Xia, Ermias Lemma Tilahun, Eyob Hailu Kebede, Terry-Elinor Reid, Liangren Zhang & Xiang Simon Wang. (2015) Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families. Journal of Chemical Information and Modeling 55:2, pages 374-388.
Crossref
Teng Ai, Yanli Xu, Li Qiu, Robert J. Geraghty & Liqiang Chen. (2014) Hydroxamic Acids Block Replication of Hepatitis C Virus. Journal of Medicinal Chemistry 58:2, pages 785-800.
Crossref
Pierfausto Seneci. 2015. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease 135 172 .
Isabella Venza, Maria Visalli, Rosaria Oteri, Diana Teti & Mario Venza. (2014) Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. International Immunopharmacology 21:2, pages 439-446.
Crossref
Jane J. Sung, Katherine Ververis & Tom C. Karagiannis. (2014) Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. Journal of Photochemistry and Photobiology B: Biology 131, pages 104-112.
Crossref
Valérie Plaisance, Laure Rolland, Valéry Gmyr, Jean-Sébastien Annicotte, Julie Kerr-Conte, François Pattou & Amar Abderrahmani. (2014) The Class I Histone Deacetylase Inhibitor MS-275 Prevents Pancreatic Beta Cell Death Induced by Palmitate. Journal of Diabetes Research 2014, pages 1-7.
Crossref
J S Riley, R Hutchinson, D G McArt, N Crawford, C Holohan, I Paul, S Van Schaeybroeck, M Salto-Tellez, P G Johnston, D A Fennell, K Gately, K O'Byrne, R Cummins, E Kay, P Hamilton, I Stasik & D B Longley. (2013) Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death & Disease 4:12, pages e951-e951.
Crossref
Charles M. MarsonChristopher J. MatthewsElena YiannakiStephen J. AtkinsonPeter E. SodenLena ShuklaNermina LamademaN. Shaun B. Thomas. (2013) Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a N -(2-Aminophenyl)benzamide Binding Unit . Journal of Medicinal Chemistry 56:15, pages 6156-6174.
Crossref
Bo Cai, Hui Lyu, Jingcao Huang, Shuiliang Wang, Choon-Kee Lee, Chunji Gao & Bolin Liu. (2013) Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Letters 335:2, pages 343-350.
Crossref
Denise A. YardleyRoohi R. Ismail-KhanBohuslav MelicharMikhail LichinitserPamela N. MunsterPamela M. KleinScott CruickshankKathy D. MillerMin J. LeeJane B Trepel. (2013) Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor. Journal of Clinical Oncology 31:17, pages 2128-2135.
Crossref
S Wang, J Huang, H Lyu, C-K Lee, J Tan, J Wang & B Liu. (2013) Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease 4:3, pages e556-e556.
Crossref
Na Liu, Song He, Li Ma, Murugavel Ponnusamy, Jinhua Tang, Evelyn Tolbert, George Bayliss, Ting C. Zhao, Haidong Yan & Shougang Zhuang. (2013) Blocking the Class I Histone Deacetylase Ameliorates Renal Fibrosis and Inhibits Renal Fibroblast Activation via Modulating TGF-Beta and EGFR Signaling. PLoS ONE 8:1, pages e54001.
Crossref
Christopher L. Cubitt, Jiliana Menth, Jana Dawson, Gary V. Martinez, Parastou Foroutan, David L. Morse, Marilyn M. Bui, G. Douglas Letson, Daniel M. Sullivan & Damon R. Reed. (2013) Rapid Screening of Novel Agents for Combination Therapy in Sarcomas. Sarcoma 2013, pages 1-12.
Crossref
Angela Nebbioso, Vincenzo Carafa, Rosaria Benedetti & Lucia Altucci. (2012) Trials with ‘epigenetic’ drugs: An update. Molecular Oncology 6:6, pages 657-682.
Crossref
. (2012) Current World Literature. Current Opinion in Oncology 24:6, pages 756-768.
Crossref
Omar Khan & Nicholas B La Thangue. (2011) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology & Cell Biology 90:1, pages 85-94.
Crossref
Christopher Chang. 2012. Epigenetics in Human Disease. Epigenetics in Human Disease 225 251 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.